About DMD disorder
About DMD disorder
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. А particular gene on the X chromosome that, when flawed (mutated), leads to DMD.
SYMPTOMS
The first signs of the disease include:
Clumsy (heavy) gait, walking on tiptoes due to increased tone in the calf muscles
Constant fatigue
Frequent falls
Difficulty performing motor skills such as running or jumping
Gowers' sign (the child helps himself to stand up using his hands)
Increased lumbar lordosis
Contractures (a shortening of muscles, tendons, skin, and nearby soft tissues that causes the joints to shorten and become very stiff, preventing normal movement)
Progressive proximal muscle weakness in the legs and pelvis. Over time this weakness spreads to the arms, neck and other parts of the body. Pseudohypertrophy (enlargement of the calf and deltoid muscles; patients experience difficulty climbing stairs)
Loss of the ability to walk by the age of 12
Skeletal deformities (scoliosis)
PREVALENCE
Duchenne muscular dystrophy affects approximately 1 in 4,000 individuals, making it the most common type of muscular dystrophy. Typically, DMD affects only males, while females can sometimes be carriers of the disease. Mutations in the dystrophin gene can be inherited or arise spontaneously.
CAUSES AND INHERITANCE PATTERN
Duchenne muscular dystrophy is inherited in an X-linked recessive pattern and is caused by a mutation in the gene that codes the dystrophin protein. There are over 250,000 patients worldwide with this diagnosis. Symptoms typically appear by the age of 5. The disease predominantly affects boys. The average lifespan of individuals with DMD ranges from adolescence to 20-30 years.
DIAGNOSIS
A blood test to check CK (creatine kinase) and other enzyme levels.
Genetic testing that can detect mutations in the Xp21 gene.
Muscle biopsy.
TREATMENT
Regular corticosteroid therapy (Deflazacort hormone) helps slow the progression of the disease. In June 2023 the FDA (U.S. Food and Drug Administration) approved the gene therapy ELEVIDYS for the treatment of Duchenne muscular dystrophy.